Magnesium oxide nanoparticles (MgO-NPs) were synthesized using the fungal strain Aspergillus terreus S1 to overcome the disadvantages of chemical and physical methods. The factors affecting the biosynthesis process were optimized as follows: concentration of Mg(NO₃)₂·6H₂O precursor (3 mM), contact time (36 min), pH (8), and incubation temperature (35 °C). The characterization of biosynthesized MgO-NPs was accomplished using UV-vis spectroscopy, Fourier transform infrared (FT-IR) spectroscopy, transmission electron microscopy (TEM), scanning electron microscopy—energy dispersive X-ray (SEM-EDX), X-ray diffraction (XRD), and dynamic light scattering (DLS). Data confirmed the successful formation of crystallographic, spherical, well-dispersed MgO-NPs with a size range of 8.0–38.0 nm at a maximum surface plasmon resonance of 280 nm. The biological activities of biosynthesized MgO-NPs including antimicrobial activity, biotreatment of tanning effluent, and chromium ion removal were investigated. The highest growth inhibition of pathogenic Staphylococcus aureus, Bacillus subtilis, Pseudomonas aeruginosa, Escherichia coli, and Candida albicans was achieved at 200 μg mL^–1 of MgO-NPs. The biosynthesized MgO-NPs exhibited high efficacy to decolorize the tanning effluent (96.8 ± 1.7% after 150 min at 1.0 µg mL^–1) and greatly decrease chemical parameters including total suspended solids (TSS), total dissolved solids (TDS), biological oxygen demand (BOD), chemical oxygen demand (COD), and conductivity with percentages of 98.04, 98.3, 89.1, 97.2, and 97.7%, respectively. Further, the biosynthesized MgO-NPs showed a strong potential to remove chromium ions from the tanning effluent, from 835.3 mg L^–1 to 21.0 mg L^–1, with a removal percentage of 97.5%.

In the wake of the emergence and worldwide respread of a viral infection called Monkeypox (Mpox), there is a serious threat to the health and safety of the global population. This viral infection was endemic to the western and central parts of Africa, but has recently spread out of this endemic area to various countries, including the United Kingdom (UK), Portugal, Spain, the United States of America (USA), Canada, Sweden, Belgium, Italy, Australia, Germany, France, the Netherlands, Israel, and Mexico. This is a timely review focusing on recent findings and developments in the epidemiology, clinical features, therapeutic targets, diagnosis, prevention mechanisms, research challenges and possible treatment for Mpox. To date (29 November 2022), there have been around 81,225 reported cases of Mpox. In most cases, this illness is mild; however, there is a fatality rate ranging from 1 to 10%, which might be increased due to associated complications and/or secondary infections. There is a real challenge in the diagnosis of Mpox, since its symptoms are very similar to those of other infections, including smallpox and chickenpox. Generally, to prevent/limit the risk and transmission of Mpox, the detection and isolation of infected individuals, as well as hand hygiene and cleanliness, are essential and effective approaches to control/combat this viral infection. Nevertheless, updated information about Mpox from different angles is lacking. Thus, this review provides updated and comprehensive information about the Mpox illness, which should highlight the global burden, pathogenicity, symptoms, diagnosis, prevention measures and possible treatment of this emerging disease.

The ability of microorganisms to reduce inorganic metals has launched an exciting eco-friendly approach towards developing green nanotechnology. Thus, the synthesis of metal nanoparticles through a biological approach is an important aspect of current nanotechnology. In this study, Streptomyces aizuneusis ATCC 14921 gave the small particle of silver nanoparticles (AgNPs) a size of 38.45 nm, with 1.342 optical density. AgNPs produced by Streptomyces aizuneusis were characterized by means of UV-VIS spectroscopy and transmission electron microscopy (TEM). The UV-Vis spectrum of the aqueous solution containing silver ion showed a peak between 410 to 430. Moreover, the majority of nanoparticles were found to be a spherical shape with variables between 11 to 42 nm, as seen under TEM. The purity of extracted AgNPs was investigated by energy dispersive X-ray analysis (EDXA), and the identification of the possible biomolecules responsible for the reduction of Ag⁺ ions by the cell filtrate was carried out by Fourier Transform Infrared spectrum (FTIR). High antimicrobial activities were observed by AgNPs at a low concentration of 0.01 ppm, however, no deleterious effect of AgNPs was observed on the development and occurrence of Drosophila melanogaster phenotype. The highest reduction in the viability of the human lung carcinoma and normal cells was attained at 0.2 AgNPs ppm.

There has been a substantial rise in the number of vancomycin-resistant Staphylococcus aureus (VRSA) strains during the last several years. The proportion of vancomycin-resistant strains among isolated S. aureus has risen steadily in recent years, with the first spike occurring in critical care units and thereafter in general hospital wards. S. aureus isolates from urinary tract infection patients were studied for their prevalence and antibiotic resistance. From 292 urine samples, 103 bacterial strains (35.3%) were identified as S. aureus. Various antibiotics were used to test the isolates’ antibacterial resistance profiles. Antibiotic resistance to erythromycin was found in most bacterial isolates, whereas tobramycin antibiotic sensitivity was found in most of them. Vancomycin resistance was found in 23 of all S. aureus isolates in this study. Analysis for β-lactamase found that 71% of S. aureus isolates were positive in all isolates. There was a single plasmid with a molecular weight of 39.306 Kbp in five selected VRSA isolates that was subjected to plasmid analysis. There was evidence of vancomycin resistance among the S. aureus isolates collected from UTI patients in this investigation. This vancomycin resistance pretenses a challenge in the treatment of S. aureus infections and the need to precisely recognize persons who require last-resort medication such as tobramycin.

Raw milk is a significant vehicle for the transmission of different infections. In the present study, we focused on Salmonella enterica from raw milk and its resistance to various antibacterial drugs. Furthermore, we have investigated the antimicrobial and antibiofilm effects of essential oil (EO) obtained from Salvia officinalis L. leaves that were collected from the Aljouf region, Saudi Arabia, against S. enterica. One-dozen strains of S. enterica were found in a batch of a hundred milk samples, and those S. enterica strains were shown to be resistant to several antibiotics, particularly the β-lactam group of antimicrobial drugs. Against multidrug-resistant S. enterica, the inhibitory zones for EO from S. officinalis leaves were found to be 21 mm in diameter. S. officinalis EO at 5% concentration showed a remarkable in vitro inhibitory activity toward the biofilm growth of different S. enterica isolates. Analysis of EO by GC–MS identified 21 distinct components, accounting for 89.94% of the total oil component. The most prominent compounds were 1,8-cineole (39.18%), β-caryophyllene (12.8%), and α--terpineol (10.3%). Taken together, our results unequivocally confirm that the S. officinalis EOs exert numerous bioactivities. Thus, the well-deserved attention on S. officinalis EO usage as a food preservative and adjunctive remedy for bacterial food-borne diseases is justified.

Introduction: Exopolysaccharides (EPSs) derived from marine microorganisms are a newly recognized reservoir of bioactive therapeutic compoundsMaterial and methods: We isolated a high EPS-yielding bacterial strain from the Red Sea, identified as Bacillus rugosus SYG20. Its purified EPS (EPSR9) contains 45.33% uronic acid, 9.98% sulfate groups, and 5.40% N-acetyl glucosamine. The HPLC chromatogram revealed four monosaccharides - glucose, xylose, galacturonic acid, and arabinose, in a distinct molar ratio of 2:3:1:1. EPSR9 showed a wide array of bioactivities.Results: It displayed antioxidant activity with an IC50 of 25.6 μg/ml in the DPPH assay and a total antioxidant capacity (TAC) of 417.77μg/ml equivalent AAE and 62.67 μg/ml equivalent AAE in Ferric reducing antioxidant power (FRAP) assays. It exhibited substantial anti-inflammatory properties. The anticoagulant effect of the EPS was demonstrated by a dose-dependent increase in prothrombin time. The scratch assay resulted in a 72.66% increase in wound closure, promoting in vitro wound healing after 48 h. Anti-obesity activity was evidenced by 83.8% lipase inhibition at 1000 μg/ml with IC50 of 107.73μg/ml. EPSR9 demonstrated inhibitory effects on α-amylase with an IC50 value of 14.37μg/ml and α-glucosidase with an IC50 value of 26.73 μg/ml, highlighting its potential as an anti-diabetic agent. Then, EPS showed bactericidal properties with MBC/MIC≤2 against both G+ve and G-ve bacteria, Staphylococcus aureus , Enterococcus faecalis (MIC=3.9μg/ml), Salmonella typhi, and Helicobacter pylori.Conclusions: The marine EPSR9 exhibited considerable potential for pharmaceutical applications as a multi-bioactive microbial metabolite. Its in vivo potency and mechanisms of action warrant further investigation.